Business
World awaits landmark US Supreme Court decision on Trump’s tariffs
Natalie ShermanBusiness reporter
ReutersWhat may be the biggest battle yet in Donald Trump’s trade war is about to begin.
The Trump administration heads to the US Supreme Court on Wednesday, facing off against small businesses and a group of states who contend most of the tariffs it has put in place are illegal and should be struck down.
If the court agrees with them, Trump’s trade strategy would be upended, including the sweeping global tariffs he first announced in April. The government would also likely have to refund some of the billions of dollars it has collected through the tariffs, which are taxes on imports.
The final decision from the justices will come after what could be months of poring over the arguments and discussing the merits of the case. Eventually they will hold a vote.
Trump has described the fight in epic terms, warning a loss would tie his hands in trade negotiations and imperil national security.
On Sunday, the president said he will not attend the hearing in person as he did not want to cause a distraction.
“I wanted to go so badly… I just don’t want to do anything to deflect the importance of that decision,” he said. “It’s not about me, it’s about our country.”
Trump previously said that if he does not win the case the US will be “weakened” and in a “financial mess” for many years to come.
The stakes feel just as high for many businesses in the US and abroad, which have been paying the price while getting whipped about by fast-changing policies.
Trump’s tariffs will cost Learning Resources, a US seller of toys made mostly overseas and one of the businesses suing the government, $14m (£10.66m) this year. That is seven times what it spent on tariffs in 2024, according to CEO Rick Woldenberg.
“They’ve thrown our business into unbelievable disruption,” he said, noting the company has had to shift the manufacturing of hundreds of items since January.
Few businesses, though, are banking on a win at the court.
“We are hopeful that this is going to be ruled illegal but we’re all also trying to prepare that it’s setting in,” said Bill Harris, co-founder of Georgia-based Cooperative Coffees.
His co-op, which imports coffee from more than a dozen countries, has already paid roughly $1.3m in tariffs since April.
A test to Trump’s presidential power
In deciding this case, the Supreme Court will have to take on a broader question: How far does presidential power go?
Legal analysts say it is hard to predict the justices’ answer, but a ruling siding with Trump will give him and future White House occupants greater reach.
Specifically, the case concerns tariffs that the Trump administration imposed using the 1977 International Emergency Economic Powers Act (IEEPA), which the White House has embraced for its speed and flexibility. By declaring an emergency under the law, Trump can issue immediate orders and bypass longer, established processes.
Trump first invoked the law in February to tax goods from China, Mexico and Canada, saying drug trafficking from those countries constituted an emergency.
He deployed it again in April, ordering levies ranging from 10% to 50% on goods from almost every country in the world. This time, he said the US trade deficit – where the US imports more than it exports – posed an “extraordinary and unusual threat”.
Those tariffs took hold in fits and starts this summer while the US pushed countries to strike “deals”.
Opponents say the law authorises the president to regulate trade but never mentions the word “tariffs”, and they contend that only Congress can establish taxes under the US Constitution.
They have also challenged whether the issues cited by the White House, especially the trade deficit, represent emergencies.
Members of Congress from both parties have asserted the Constitution gives them responsibility for creating tariffs, duties and taxes, as well.
More than 200 Democrats in both chambers and one Republican, Senator Lisa Murkowski, filed a brief to the Supreme Court, where they also argued the emergency law did not grant the president power to use tariffs as a tool for gaining leverage in trade talks.
Meanwhile, last week the Senate made a symbolic and bipartisan move to pass three resolutions rejecting Trump’s tariffs, including one to end the national emergency he declared. They are not expected to be approved in the House.
Still, business groups said they hoped the rebuke would send a message to the justices.
‘An energy drain like I’ve never seen’
Three lower courts have ruled against the administration. After the Supreme Court hears arguments on Wednesday it will have until June to issue its decision, although most expect a ruling to come by January.
Whatever it decides has implications for an estimated $90bn worth of import taxes already paid – roughly half the tariff revenue the US collected this year through September, according to Wells Fargo analysts.
Trump officials have warned that sum could swell to $1tn if the court takes until June.
Cafe CampesinoIf the government is forced to issue refunds, Cooperative Coffees will “absolutely” try to recoup its money, said Mr Harris, but that would not make up for all the disruption.
His business has had to take out an extra line of credit, raise prices and find ways to survive with lower profits.
“This is an energy drain like I’ve never seen,” said Mr Harris, who is also chief financial officer of Cafe Campesino, one of the 23 roasteries that own Cooperative Coffees. “It dominates all the conversations and it just kind of sucks the life out of you.”
What could happen next?
The White House says that if it loses, it will impose levies via other means, such as a law allowing the president to put tariffs of up to 15% in place for 150 days.
Even then, businesses would have some relief, since those other means require steps like issuing formal notices, which take time and deliberation, said trade lawyer Ted Murphy of Sidley Austin.
“This is not just about the money,” he said. “The president has announced tariffs on Sunday that go into effect on Wednesday, without advance notice, without any real process.”
“I think that’s the bigger thing for this case for businesses – whether or not that is going to be in our future,” he added.
There is no clear sign of how the court will rule.
In recent years it has struck down major policies, such as Biden-era student loan forgiveness, as White House overreach.
But the nine justices, six of whom were appointed by Republicans, including three by Trump, have shown deference to this president in other recent disputes and historically have given leeway to the White House on questions of national security.
“I really do think arguments are available for the Supreme Court to go in all different directions,” said Greta Peisch, partner at Wiley and former trade lawyer in the Biden administration.
Adam White, senior fellow at the American Enterprise Institute, said he expected the court to strike down the tariffs, but avoid questions like what constitutes a national emergency.
ReutersThe case has already complicated the White House’s trade deals, such as one struck in July with the European Union.
The European Parliament is currently considering ratifying the agreement, which sets US tariffs on European goods at 15% in exchange for promises including allowing in more US agricultural products.
“They’re not going to act on this until they see the outcome of the Supreme Court decision,” said John Clarke, former director for international trade at the European Commission.
Chocolats Camille BlochIn Switzerland, which recently downgraded its outlook for economic growth citing America’s 39% tariff on its goods, chocolatier Daniel Bloch said he’d welcome a ruling against the Trump administration.
His business Chocolats Camille Bloch is absorbing about a third of the cost of new tariffs on kosher chocolate that his firm has exported to the US for decades, aiming to blunt price increases and maintain sales. That decision has wiped out profits for the unit and is not sustainable, he said.
He hopes Trump will reconsider his tariffs altogether, because “that would be easiest”.
“If the court were to make the tariffs go away of course we would see that as a positive sign,” he said. “But we don’t trust that that will bring the solution.”
Business
Kimberly-Clark agrees to buy Tylenol owner Kenvue in $48.7 billion deal, creating consumer staples giant
Huggies, manufactured by Kimberly-Clark and Band-Aid, manufactured by Kenvue.
Getty Images
Kimberly-Clark announced Monday it’s struck an agreement to buy Kenvue in a deal valued at $48.7 billion that would create a consumer staples giant.
The deal is a combination of cash and stock and totals about $40 billion on an equity basis, excluding the impact of debt. Shares of Kenvue surged 15% Monday, while Kimberly-Clark stock fell 13%.
The combined company would bring together brands like Huggies and Kleenex with the likes of Band-Aid and Tylenol. It would include 10 billion-dollar brands, the companies said in a news release. The acquisition would be one of the largest on Wall Street this year.
The transaction is expected to close in the second half of 2026.
Kimberly-Clark Chairman and CEO Mike Hsu said in a statement that the companies share a “commitment to developing science and technology to provide extraordinary care.”
“Over the last several years, Kimberly-Clark has undertaken a significant transformation to pivot our portfolio to higher-growth, higher-margin businesses while rewiring our organization to work smarter and faster,” Hsu said. “We have built the foundation and this transaction is a powerful next step in our journey.”
Kenvue, a portfolio of consumer health brands, spun out of Johnson & Johnson in May 2023, marking the biggest shake-up in J&J’s nearly 140-year history. Since then, Kenvue shares have fallen almost 35% from their initial public offering price. As of Friday’s close, Kenvue traded at about $14 per share for a market cap of roughly $27 billion.
J&J has sold all of its remaining stake in the consumer goods giant.
The deal comes just weeks after President Donald Trump made unfounded claims linking the use of acetaminophen — the active ingredient in Tylenol — during pregnancy to an increased risk of autism, sending Kenvue’s stock sharply lower. The company has staunchly pushed back against his administration’s accusation, and many medical experts say Tylenol is often the safest and only option for pain and fever relief in pregnant women.
Acetaminophen is used by upward of 100 million Americans annually.
Kenvue Chair Larry Merlo said in a statement that following a comprehensive strategic review, the board is “confident this combination represents the best path forward for our shareholders and all other stakeholders.”
Three Kenvue board members will join the Kimberly-Clark board upon the deal’s closing. Hsu will continue to serve as chairman and CEO.
The combined company would generate estimated 2025 annual net revenue of roughly $32 billion and adjusted earnings before interest, taxes, depreciation and amortization of approximately $7 billion, according to the release.
Kimberly-Clark and Kenvue expect about $1.9 billion in cost synergies from the transaction to be realized in the first three years following the deal’s close.
The acquisition comes as Kimberly-Clark and the broader consumer packaged goods industry try to address shifting demand and shopping behavior, often through deal-making and divestitures.
Tariffs imposed by Trump’s administration have challenged the industry and its profits as key commodities like pulp, which is used to make tissues and diapers, grow more expensive.
At the beginning of 2025, Kimberly-Clark stopped making private-label diapers for Costco to focus on more premium brands that command higher margins.
In June, the company sold a majority stake in its international tissue business to Brazilian pulp maker Suzano. The resulting joint venture is intended to shield Kimberly-Clark from volatile input costs and help stabilize its margins.
Once the deal closes, Kimberly-Clark will own health-care brands like Sudafed and Pepcid, once again pitting the company against rival Procter & Gamble, which has a health-care division that includes Pepto-Bismol and Vicks.
But even with Kimberly-Clark’s blockbuster acquisition, P&G still dwarfs its rival in both enterprise value and annual revenue. P&G has a market cap of about $350 billion.
Similar to Kenvue, other spinoffs have also recently proven to be popular acquisition targets. Last year, candy maker Mars announced plans to buy Kellanova, a snacking-centric spinoff of Kellogg, while Ferrero bought W.K. Kellogg, the cereal stand-alone, this year.
Business
India, New Zealand Hold 4th FTA Talks In Auckland On Trade Rules
New Delhi: The fourth round (November 3-7, 2025) of negotiations for the India-New Zealand Free Trade Agreement (FTA) commenced on Monday in Auckland, New Zealand, marking another step forward in advancing a balanced, comprehensive, and mutually beneficial partnership between the two nations.
According to India’s commerce ministry, this development builds on the shared commitment to deepen economic ties and guidance given by Prime Minister Narendra Modi during the visit of the New Zealand counterpart Christopher Luxon, Prime Minister in March 2025.
The FTA was launched during the meeting between Piyush Goyal, Minister of Commerce and Industry, Todd McClay, Minister for Trade and Investment, New Zealand on March 16, 2025.
Negotiations in this round are focusing on key areas, including Trade in Goods, Trade in Services, and Rules of Origin, the commerce ministry said in a statement today.
“Both sides are working constructively to build on the progress achieved in earlier rounds, to reach convergence on outstanding issues and move towards the early conclusion of the FTA,” the statement added
India and New Zealand reiterated their commitment to developing a forward-looking and inclusive trade framework that supports sustainable growth and shared prosperity for both economies.
India is actively negotiating trade agreements with nearly a dozen countries, including the United States, the European Union, Australia, Sri Lanka, Qatar, and several others, in a bid to expand trade and secure long-term growth opportunities.
The coming months are expected to be critical, when the outcomes of these negotiations could redefine India’s role in the global trade architecture and shape its economic trajectory for the next decade.
India has, over the past 5 years, inked several trade deals, including the India-Mauritius Comprehensive Economic Cooperation and Partnership Agreement (CECPA) implemented in 2021, the India-UAE Comprehensive Economic Partnership Agreement (CEPA) and the India-Australia Economic Cooperation and Trade Agreement (ECTA) in 2022, the India-European Free Trade Association (EFTA) Trade and Economic Partnership Agreement (TEPA) in 2024, and the India-UK Comprehensive Economic and Trade Agreement (CETA) signed in 2025, which is understandably yet to come into force.
Negotiations for a comprehensive trade deal between India and Oman, which commenced in 2023, were recently concluded.
Business
Consumer healthcare mega merger: Kimberly-Clark to acquire Tylenol maker Kenvue in $48.7 billion cash and stock deal; $1.9 billion cost savings targeted post-merger – The Times of India
Kimberly-Clark is set to acquire Tylenol maker Kenvue in a cash-and-stock transaction valued at approximately $48.7 billion, creating one of the world’s largest consumer health goods companies, AP reported.Under the terms of the agreement, Kenvue shareholders will receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held at closing. Based on Kimberly-Clark’s closing share price on Friday, the deal values Kenvue stock at $21.01 per share.Following the merger, Kimberly-Clark shareholders will own around 54% of the combined entity, while Kenvue shareholders will hold about 46%. The companies said the merger is expected to generate annual net revenues of approximately $32 billion in 2025. They also identified an estimated $1.9 billion in cost savings to be realised within the first three years after the deal closes.“With a shared commitment to developing science and technology to provide extraordinary care, we will serve billions of consumers across every stage of life,” said Kimberly-Clark Chairman and CEO Mike Hsu in a statement.Hsu will lead the merged company as chairman and CEO, while three members of Kenvue’s board will join Kimberly-Clark’s board upon closing. The combined company will retain Kimberly-Clark’s headquarters in Irving, Texas, and maintain a significant presence at Kenvue’s existing locations.The acquisition is expected to close in the second half of next year, pending approval from shareholders of both companies.In early trading, Kimberly-Clark shares dropped more than 15% before the market open, while Kenvue’s stock surged over 20%.
-
Tech6 days agoOpenAI says a million ChatGPT users talk about suicide
-
Tech6 days agoHow digital technologies can support a circular economy
-
Tech6 days agoUS Ralph Lauren partners with Microsoft for AI shopping experience
-
Tech6 days agoAI chatbots are becoming everyday tools for mundane tasks, use data shows
-
Fashion6 days agoITMF elects new board at 2025 Yogyakarta conference
-
Business6 days agoTransfer test: Children from Belfast low income families to be given free tuition
-
Entertainment1 week agoGrimes backs Selena Gomez after ‘In The Dark’ video
-
Fashion1 week agoTaiwan Textile Select showcases sustainable innovation at TITAS 2025

